Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
10.71
-0.04 (-0.37%)
At close: Oct 30, 2026, 4:00 PM EDT
10.74
+0.03 (0.26%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year. That makes Xeris Biopharma Holdings the 21,186th largest employer in the world and 2,782nd in the United States.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$771,067
Profits / Employee
-$39,460
Market Cap
1.95B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,605 |
| HUTCHMED (China) | 1,790 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Pacira BioSciences | 829 |
XERS News
- 8 days ago - Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Business Wire
- 15 days ago - Xeris announces presentations on portfolio, pipeline at scientific meetings - TheFly
- 15 days ago - Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings - Business Wire
- 24 days ago - Xeris Biopharma price target raised to $14 from $12 at Barclays - TheFly
- 4 weeks ago - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Reuters
- 4 weeks ago - Lundbeck exploring acquisition of Xeris, Bloomberg reports - TheFly
- 4 weeks ago - Xeris Biopharma tells Bloomberg ‘not for sale’ - TheFly